|
Gene: GALR2 |
Gene summary for GALR2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | GALR2 | Gene ID | 8811 |
Gene name | galanin receptor 2 | |
Gene Alias | GAL2-R | |
Cytomap | 17q25.1 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | O43603 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8811 | GALR2 | P4T-E | Human | Esophagus | ESCC | 4.35e-18 | 5.03e-01 | 0.1323 |
8811 | GALR2 | P30T-E | Human | Esophagus | ESCC | 1.02e-02 | 1.89e-01 | 0.137 |
8811 | GALR2 | P47T-E | Human | Esophagus | ESCC | 9.53e-09 | 1.97e-01 | 0.1067 |
8811 | GALR2 | P89T-E | Human | Esophagus | ESCC | 5.43e-13 | 5.65e-01 | 0.1752 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ESCC: Esophageal squamous cell carcinoma | |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | |
Endometrium | AEH | |
Endometrium | EEC | |
Prostate | BPH | |
Prostate | Tumor |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
GO:00060668 | Esophagus | ESCC | alcohol metabolic process | 202/8552 | 353/18723 | 7.32e-06 | 7.26e-05 | 202 |
GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
GAL | GALR2 | GAL_GALR2 | GALANIN | Esophagus | ESCC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GALR2 | SNV | Missense_Mutation | c.213N>A | p.Asp71Glu | p.D71E | O43603 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
GALR2 | SNV | Missense_Mutation | c.541N>A | p.Ala181Thr | p.A181T | O43603 | protein_coding | tolerated(0.58) | benign(0.047) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GALR2 | SNV | Missense_Mutation | novel | c.820N>T | p.Arg274Cys | p.R274C | O43603 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
GALR2 | SNV | Missense_Mutation | c.821N>A | p.Arg274His | p.R274H | O43603 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GALR2 | SNV | Missense_Mutation | c.647N>A | p.Arg216His | p.R216H | O43603 | protein_coding | tolerated(0.16) | probably_damaging(0.93) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GALR2 | SNV | Missense_Mutation | novel | c.434C>T | p.Ala145Val | p.A145V | O43603 | protein_coding | tolerated(0.07) | possibly_damaging(0.863) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GALR2 | SNV | Missense_Mutation | novel | c.815C>T | p.Ala272Val | p.A272V | O43603 | protein_coding | tolerated(0.71) | benign(0.228) | TCGA-AJ-A5DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GALR2 | SNV | Missense_Mutation | novel | c.64N>T | p.His22Tyr | p.H22Y | O43603 | protein_coding | deleterious(0.01) | benign(0.044) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
GALR2 | SNV | Missense_Mutation | c.760N>A | p.Ala254Thr | p.A254T | O43603 | protein_coding | tolerated(0.16) | benign(0.098) | TCGA-BS-A0TC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GALR2 | SNV | Missense_Mutation | rs751959289 | c.688G>A | p.Ala230Thr | p.A230T | O43603 | protein_coding | deleterious(0.01) | probably_damaging(0.956) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8811 | GALR2 | G PROTEIN COUPLED RECEPTOR, KINASE, DRUGGABLE GENOME | agonist | 178102729 | ||
8811 | GALR2 | G PROTEIN COUPLED RECEPTOR, KINASE, DRUGGABLE GENOME | agonist | 178102743 | ||
8811 | GALR2 | G PROTEIN COUPLED RECEPTOR, KINASE, DRUGGABLE GENOME | agonist | 178102722 | ||
8811 | GALR2 | G PROTEIN COUPLED RECEPTOR, KINASE, DRUGGABLE GENOME | agonist | 178102724 | ||
8811 | GALR2 | G PROTEIN COUPLED RECEPTOR, KINASE, DRUGGABLE GENOME | agonist | 178102733 | ||
8811 | GALR2 | G PROTEIN COUPLED RECEPTOR, KINASE, DRUGGABLE GENOME | agonist | 178102762 | ||
8811 | GALR2 | G PROTEIN COUPLED RECEPTOR, KINASE, DRUGGABLE GENOME | agonist | 178102697 | ||
8811 | GALR2 | G PROTEIN COUPLED RECEPTOR, KINASE, DRUGGABLE GENOME | agonist | 178102761 | ||
8811 | GALR2 | G PROTEIN COUPLED RECEPTOR, KINASE, DRUGGABLE GENOME | agonist | 178102019 | ||
8811 | GALR2 | G PROTEIN COUPLED RECEPTOR, KINASE, DRUGGABLE GENOME | agonist | 178102715 |
Page: 1 2 3 4 5 6 |